<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Sat, 05 Dec 2009 19:11:50 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>Welichem announces special meeting results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3186279</guid>
      <description><![CDATA[BURNABY, BC, April 8 /CNW/ - Welichem Biotech Inc. (&quot;Welichem&quot; or the &quot;Company&quot;) (TSX-V: WBI) announces that the Company held its special meeting of shareholders (the &quot;Special Meeting&quot;) on Monday, April 6, 2009. The Company's shareholders passed a special resolution to approve the proposed consolidation of all of the Company's issued and outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares. The name of the Company will not be changed in conjunction with the proposed share consolidation.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3186279>[More...]</a>]]></description>
      <pubDate>Wed, 08 Apr 2009 18:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3186279</link>
    </item>
    <item>
      <title>Wenfeng Liu and York Ying Ping Guo Resign as Directors</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3114463</guid>
      <description><![CDATA[BURNABY, BC, March 12 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI), announced that Messrs. Wenfeng Liu and York Ying Ping Guo have resigned as directors of the Company effective today.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3114463>[More...]</a>]]></description>
      <pubDate>Fri, 13 Mar 2009 00:58:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3114463</link>
    </item>
    <item>
      <title>Welichem Proposes Share Consolidation</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3106613</guid>
      <description><![CDATA[BURNABY, BC, March 10 /CNW/ - Welichem Biotech Inc. (&quot;Welichem&quot; or the &quot;Company&quot;) (TSX-V: WBI) announces that the Company will hold a special general meeting of shareholders (the &quot;Special Meeting&quot;) on Monday, April 6, 2009. The Company intends to ask its shareholders at the Special Meeting to consider and pass a special resolution to consolidate all of the issued and outstanding common shares of the Company on the basis of one (1) post-consolidation common share for every ten (10) pre-consolidation common shares. The name of the Company will not be changed in conjunction with the proposed share consolidation.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3106613>[More...]</a>]]></description>
      <pubDate>Wed, 11 Mar 2009 01:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3106613</link>
    </item>
    <item>
      <title>Welichem Reports Successful pre-CTA Meeting with Health Canada</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2983732</guid>
      <description><![CDATA[BURNABY, BC, Jan. 26 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI) is pleased to announce a successful pre-CTA (&quot;Clinical Trial Application&quot;) meeting with the Therapeutic Products Directorate (TPD) of Health Canada regarding two proposed Phase II clinical studies and a comprehensive, long-term development plan to enable a marketing application for WBI-1001 as a topical treatment for psoriasis and atopic dermatitis in Canada. The purpose of the meeting was to seek guidance and concurrence from the TPD for the proposed trials and development plan. Prior to this meeting, the Company submitted, for review by the regulators, a meeting information package to update the TPD on toxicology/safety and clinical studies conducted ...<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2983732>[More...]</a>]]></description>
      <pubDate>Mon, 26 Jan 2009 23:16:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2983732</link>
    </item>
    <item>
      <title>Welichem Announces Appointment of New CFO</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2942559</guid>
      <description><![CDATA[BURNABY, BC, Jan. 9 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI) today announces the appointment of Yue Zhao as Chief Financial Officer (CFO) of the Company, effective immediately. Ms. Yue brings in more than 16 years' financial and accounting experience from private and public companies. Ms. Yue obtained her Certified General Accountant designation from Canada in 1996 and her M.Sc. in finance from the University of British Columbia in 1998.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2942559>[More...]</a>]]></description>
      <pubDate>Sat, 10 Jan 2009 01:23:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2942559</link>
    </item>
    <item>
      <title>Welichem announces 2008 AGM Board members election</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2776184</guid>
      <description><![CDATA[BURNABY, BC, Nov. 6 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI), held its Annual and Special General Meeting on October 28, 2008 at which five Directors were elected to the Board. Shareholders re-elected York Ying Ping Guo and Wenfeng Liu as directors. New directors elected for the coming year were Dr. Tan Xiangdong, Yi Meilin and Frank Li.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2776184>[More...]</a>]]></description>
      <pubDate>Thu, 06 Nov 2008 21:31:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2776184</link>
    </item>
    <item>
      <title>Welichem Reports Positive Phase IIa Clinical Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2755102</guid>
      <description><![CDATA[BURNABY, BC, Oct. 30 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI) is pleased to announce the positive results from its Phase IIa clinical trial of its drug candidate, WBI-1001, a new, non-steroid, topical cream treatment for atopic dermatitis (AD). In the trial, two concentrations (0.5% and 1.0%) of WBI-1001 were tested against the placebo. Both WBI-1001 cream concentrations were superior to placebo in deceasing AD and showed an excellent safety profile. Welichem plans to conduct further clinical trials for WBI-1001 in 2009. &quot;We are very pleased to be able to present such positive results from the Company's clinical trial on atopic dermatitis,&quot; says Dr. Genhui Chen, Chief Executive Officer of Welichem.&quot; AD is a major unmet medical ...<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2755102>[More...]</a>]]></description>
      <pubDate>Fri, 31 Oct 2008 01:44:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2755102</link>
    </item>
    <item>
      <title>Dr. Yeyan Zhang Resigns as a Director</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2684575</guid>
      <description><![CDATA[BURNABY, BC, Oct. 6 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI), announced that Dr. Yeyan Zhang has resigned as a director of the Company for personal reasons. The Company has greatly valued Dr. Yeyan Zhang's contribution as a director of the Company for the past few years.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2684575>[More...]</a>]]></description>
      <pubDate>Mon, 06 Oct 2008 22:37:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2684575</link>
    </item>
    <item>
      <title>Welichem succesfully completes Phase I clinical trial</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2381134</guid>
      <description><![CDATA[BURNABY, BC, July 8 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI) is pleased to announce the successful completion of and the results from a randomized, double-blinded Phase I clinical trial done in Montreal Canada, which evaluated topically applied WBI-1001 in 36 psoriasis patients.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2381134>[More...]</a>]]></description>
      <pubDate>Tue, 08 Jul 2008 22:27:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2381134</link>
    </item>
    <item>
      <title>Welichem announces appointment of President &amp; CEO</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/2320952</guid>
      <description><![CDATA[BURNABY, BC, June 27 /CNW/ - Welichem Biotech Inc. (the &quot;Company&quot;) (TSX-V: WBI) today announces the appointment of Dr. Genhui Chen as President &amp; CEO of the Company, effective immediately. A long time director and one of the founders of the Company, he will guide Welichem through the next crucial stage of development as it realizes the potential value of its drug candidates in clinical trials.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/2320952>[More...]</a>]]></description>
      <pubDate>Fri, 27 Jun 2008 20:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">WBI</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/2320952</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=WBI" rel="self" type="application/rss+xml" />
  </channel>
</rss>